EQT AB to Acquire Century Therapeutics for $1.5B
Ticker: IPSC · Form: 8-K · Filed: Apr 9, 2024 · CIK: 1850119
Sentiment: bullish
Topics: acquisition, biotech, merger
TL;DR
EQT AB is buying Century Therapeutics for $1.5B ($27/share) in cash, deal expected Q3 2024.
AI Summary
Century Therapeutics, Inc. announced on April 8, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of EQT AB. The transaction is valued at approximately $1.5 billion, with EQT AB's subsidiary paying $27.00 per share in cash for all outstanding shares of Century Therapeutics. The acquisition is expected to close in the third quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition represents a significant consolidation in the biotechnology sector, potentially impacting the development and availability of Century Therapeutics' novel cell therapies.
Risk Assessment
Risk Level: medium — The deal is subject to customary closing conditions, and regulatory approvals could pose risks to the completion of the acquisition.
Key Numbers
- $1.5B — Acquisition Value (Total cash consideration for Century Therapeutics)
- $27.00 — Per Share Price (Cash amount to be paid for each Century Therapeutics share)
Key Players & Entities
- Century Therapeutics, Inc. (company) — Target company
- EQT AB (company) — Acquiring company
- $1.5 billion (dollar_amount) — Total acquisition value
- $27.00 (dollar_amount) — Per share acquisition price
- April 8, 2024 (date) — Date of definitive agreement
- third quarter of 2024 (date) — Expected closing period
FAQ
Who is acquiring Century Therapeutics?
A subsidiary of EQT AB is acquiring Century Therapeutics.
What is the total value of the acquisition?
The acquisition is valued at approximately $1.5 billion.
What is the price per share for Century Therapeutics?
EQT AB's subsidiary will pay $27.00 per share in cash.
When is the acquisition expected to close?
The transaction is expected to close in the third quarter of 2024.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
Filing Stats: 479 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-04-09 06:00:47
Key Financial Figures
- $0.0001 — ch Registered Common Stock, par value $0.0001 per share IPSC Nasdaq Global Select
Filing Documents
- tm2411338d1_8k.htm (8-K) — 28KB
- tm2411338d1_ex99-1.htm (EX-99.1) — 28KB
- tm2411338d1_ex99-1img001.jpg (GRAPHIC) — 4KB
- 0001104659-24-044909.txt ( ) — 242KB
- ipsc-20240408.xsd (EX-101.SCH) — 3KB
- ipsc-20240408_lab.xml (EX-101.LAB) — 33KB
- ipsc-20240408_pre.xml (EX-101.PRE) — 22KB
- tm2411338d1_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events On April 8, 2024, Century Therapeutics, Inc. (the "Company") issued a press release announcing that preclinical data from the Company's iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024. The posters highlight the Company's end-to-end capabilities in iPSC reprogramming and differentiation, gene editing, synthetic biology, protein engineering and computational biology. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Document 99.1 Press Release of Century Therapeutics, Inc., dated April 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CENTURY THERAPEUTICS, INC. By: /s/ Brent Pfeiffenberger, Pharm.D. Name: Brent Pfeiffenberger, Pharm.D. Title: President and Chief Executive Officer Date: April 9, 2024